Articles related to FDA

The potential shortage of Saxenda (liraglutide) through 2023 underscores the importance of monitoring the availability of this weight management drug. Physicians should be aware of this situation and consider alternative options if necessary.

The recent approval of epcoritamab for R/R DLBCL introduces a new pathway in treatment, offering substantial response rates and the potential for broader implementation beyond academic centers. Explore the detailed insights into the function, efficacy, and prospective implications of this novel therapy.

Suflave™, an osmotic laxative approved by the FDA for colon cleansing in adults, represents a significant development in colonoscopy preparation. Patients interested in a low-volume option with improved taste attributes will find Suflave to be a promising alternative.

The FDA’s approval of Beyfortus offers a promising tool for RSV disease prevention in neonates and young children. This novel intervention, underscored by robust clinical trial data, marks a crucial stride towards protecting infant health in the US.

Brenzavvy, the latest addition to the diabetes treatment landscape, promises a cost-effective approach to managing type 2 diabetes. Discover how this newly approved drug could redefine the treatment paradigm for patients.

FDA’s approval of Opill, the first over-the-counter daily oral contraceptive, marks a major shift in contraceptive accessibility, opening new pathways in the prevention of unintended pregnancies.